Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)

A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection

The purpose of this study is to assess the safety and antiviral activity of IDX184 in combination with pegylated interferon and ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C virus (HCV) infection.

Inclusion Criteria:

• Males and females with documented genotype 1, chronic hepatitis C infection.
• Must agree to use double-barrier method of birth control for at least 6 months after the last dose of study drugs.
• Has not received prior antiviral treatment for HCV.
• Written informed consent by participant.

Exclusion Criteria:

• Pregnant or breastfeeding.
• Co-infected with hepatitis B virus (HBV; hepatitis B surface antigen [HBsAg] positive) and/or human immunodeficiency virus (HIV).